Syra Health Corp. Class A Common Stock
SYRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.03 | -0.00 | 233.13 |
| FCF Yield | -98.36% | -56.00% | -13.45% | -0.43% |
| EV / EBITDA | -0.28 | -0.68 | -8.92 | -7,188.53 |
| Quality | ||||
| ROIC | -113.07% | -67.76% | -127.04% | -0.98% |
| Gross Margin | 20.71% | 25.54% | 18.90% | 30.52% |
| Cash Conversion Ratio | 0.78 | 0.94 | 1.06 | 26.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.42% | 57.56% | – | 1,121,239.81% |
| Free Cash Flow Growth | -6.09% | -17.29% | -2,403.31% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.53 | 1.07 | -0.45 | -79.03 |
| Interest Coverage | -241.34 | -53.79 | -73.24 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 96.51 | 0.00 |
| Cash Conversion Cycle | 25.27 | 37.23 | 56.35 | 26.19 |